托吡酯联合奥氮平对第二代抗精神病药所致体质量增加及代谢功能障碍的防治效果研究

Study on the effect of prevention and treatment of increased body mass and metabolic disturbance caused by topiramate joint with olanzapine

目的探讨托吡酯联合奥氮平对第二代抗精神病药所致体质量增加及代谢功能障碍的防治效果。方法采用前瞻性分析的方法,将2014年1月至2017年1月接受治疗的38例首发精神分裂症患者作为研究对象,并随机分为干预组(托吡酯+奥氮平)与对照组(奥氮平),每组19例,对两组患者治疗前后的体质量、代谢功能变化情况及不良反应发生率进行综合评价。结果干预组患者治疗后的体质量及体质量指数(BMI)明显低于对照组,差异有显著性(P<0.05);干预组治疗后的空腹血糖、血脂等代谢功能相关指标显著低于对照组,差异有显著性(P<0.05);干预组不良反应发生率(5.3%)明显低于对照组(31.6%),差异有显著性(P<0.05)。结论托吡酯联合奥氮平治疗能够有效防治第二代抗精神病药所致体质量增加及代谢功能障碍,且不良反应少,疗效显著,值得推广应用。

Objective To explore the control effect on increased body mass and metabolic dysfunction caused by topiramate joint with second generation antipsychotic olanzapine. Methods A total of 38 patients with first-episode schizophrenia treated in this hospital during January2014 to January 2017 were allocated for this study,and they were randomly divided into intervention group（ with topiramate ＋ olanzapine） and control group（ with olanzapine）,19 cases in each group. The changes in body quality and metabolic function in patients of these groups were compared between patients of these 2 groups before and after the treatment,and the comprehensive evaluation on the incidence of adverse reactions.Results The body mass and body mass index（ BMI） in intervention group were significantly lower than those of control group（ P 〈 0. 05）. The indexes of fasting glucose,thyroglobulin,serum total cholesterol and other metabolic functions were significantly lower than those of control group,and the difference was significant（ P 〈 0. 05）. The incidence of adverse reactions（ 5. 3%） in the intervention group was significantly lower than that（ 31. 6%） of control group,and the difference was significant（ P 〈 0. 05）. Conclusion Topiramate joint with olanzapine can effectively control the increase in body mass and metabolic dysfunction caused by second generation antipsychotic with less adverse reactions,and the curative effect is distinct,hence it is worthy to be popularized and applied.